📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

Repurposing Tin Mesoporphyrin as an Immune Checkpoint Inhibitor Shows Therapeutic Efficacy in Preclinical Models of Cancer. (2018)

First Author: Muliaditan T
Attributed to:  Defining the role of aberrant O-linked glycosylation in breast cancer funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1158/1078-0432.ccr-17-2587

PubMed Identifier: 29339440

Publication URI: http://europepmc.org/abstract/MED/29339440

Type: Journal Article/Review

Volume: 24

Parent Publication: Clinical cancer research : an official journal of the American Association for Cancer Research

Issue: 7

ISSN: 1078-0432